Vitamin D3 for Life

Live Enlightened

Article

Vitamin D and Vitamin K in Calcium Handling, Bone and Vascular Physiology: Evidence Synthesis

Previous related pageWhy Vitamin D and Vitamin K Perform Different Jobs in Calcium PhysiologyNext related pageHow Vitamin D and Vitamin K Work Together in the Body
Study at a glance

Why are vitamin D and vitamin K studied together?

Vitamin D helps regulate calcium and the production of some proteins. Vitamin K helps certain proteins function properly. Their roles meet in bone and mineral handling, but they are different jobs.

Does improving a vitamin K blood marker prove stronger bones or healthier arteries?

No. A marker can show that a protein pathway responded without showing fewer fractures or less calcification, meaning calcium deposits in tissue. Those outcomes need separate evidence.

What did the aortic-valve trial find?

Vitamin K2 plus vitamin D improved a marker linked to vitamin K-dependent protein activity. It did not significantly slow calcium build-up in the aortic valve compared with placebo over two years.

Do the findings support the combination for everyone?

No. Some bone studies found benefits in selected osteoporosis groups, while other bone and vascular results were negative. The evidence also does not show that vitamin K makes excessive vitamin D safe.

Read the full article below ↓

Vitamin D and vitamin K participate in the same broad mineral-regulatory system while performing different biochemical jobs. Vitamin D contributes to calcium absorption, endocrine calcium homeostasis and vitamin-D-responsive gene expression. Vitamin K enables gamma-carboxylation of vitamin-K-dependent proteins including osteocalcin and matrix Gla protein. This creates a genuine physiological interaction, but the clinical evidence does not support the popular simplification that vitamin D brings calcium into the body while vitamin K simply sends it to bone and away from arteries. Human trials instead show a more nuanced pattern: vitamin-K-dependent biomarkers can improve strongly, selected osteoporosis populations may gain bone benefit, and yet major bone or vascular structural outcomes can remain unchanged.

The interaction begins with different molecular functions

Vitamin D receptor signalling influences transcription in osteoblasts and contributes to osteocalcin expression. Vitamin K acts later through gamma-carboxylation, changing the functional state of osteocalcin and other vitamin-K-dependent proteins.

The mechanistic evidence is developed in Vitamin D, Vitamin K-Dependent Proteins and Calcium Handling: Full Study.

Osteocalcin demonstrates the division of labour

Active vitamin D can stimulate osteocalcin transcription in osteoblasts. Vitamin K is required for carboxylation of osteocalcin. Human osteoblast experiments show that vitamin K₂ can increase gamma-carboxyglutamate-containing osteocalcin accumulation in the extracellular matrix during active-vitamin-D exposure.

This supports complementary physiology. It does not show that either nutrient independently controls bone mineralisation or fracture risk.

Matrix Gla protein creates a related vascular mechanism

MGP is an inhibitor of inappropriate mineralisation in vascular tissues. Vitamin K-dependent carboxylation contributes to its functional state, while dp-ucMGP serves as a marker of inactive MGP and poor functional vitamin K status.

The presence of this mechanism makes combined vitamin D and vitamin K supplementation biologically plausible in vascular disease, but biological plausibility is not the same as demonstrated slowing of calcification.

Bone trials show benefit in some populations

Several randomized trials in postmenopausal osteoporosis reported larger increases in lumbar bone mineral density or reductions in undercarboxylated osteocalcin when vitamin K₂ was combined with vitamin D. A meta-analysis of eight randomized trials also found a favourable pooled effect on total BMD and undercarboxylated osteocalcin.

Those findings are described in Combined Vitamin D and Vitamin K Supplementation for Bone and Vascular Markers: Full Study.

The 2026 VITAL evidence limits generalisation

The VITAL ancillary analysis provides an important modern counterweight. Higher baseline vitamin K status was not associated with favourable two-year changes in bone density or architecture, and baseline vitamin K status did not modify the effect of vitamin D supplementation on bone mineral density.

This means the positive osteoporosis evidence cannot be generalized into the proposition that better vitamin K status makes supplemental vitamin D protect the skeleton in generally healthy adults.

Vascular trials separate protein activation from disease progression

The aortic-valve calcification trial provides perhaps the clearest example. Two years of MK-7 plus vitamin D substantially reduced dp-ucMGP, showing that the vitamin-K-dependent protein pathway responded. Yet aortic-valve calcification progression did not differ significantly from placebo.

Coronary and aortic calcification outcomes were also not significantly improved overall. A later coronary subgroup analysis suggested less progression among participants with high baseline CAC, but that subgroup result does not replace the null overall randomized finding.

Why biomarker success can coexist with structural failure

Carboxylating MGP is only one part of vascular mineral biology. Established calcification reflects phosphate exposure, kidney function, smooth-muscle-cell phenotype, inflammation, cell death, matrix changes and the history of mineral deposition. Correcting one inhibitory protein system may therefore be insufficient to reverse or materially slow an established lesion.

The same principle applies to bone. Better osteocalcin carboxylation does not guarantee a measurable change in fracture risk or BMD if other determinants dominate the skeletal system.

The interaction does not establish a universal supplement pairing

The evidence shows that vitamin D and vitamin K interact physiologically. It does not show that every person supplementing vitamin D requires vitamin K, that vitamin K prevents every adverse calcium effect, or that combined supplementation reliably improves vascular outcomes.

Requirements can also differ according to diet, medication use, kidney function, age and clinical condition. Vitamin K antagonists create a particularly different physiological context and should not be conflated with ordinary nutritional variation.

Vitamin K cannot be used as a safety valve for excessive vitamin D

No evidence reviewed here demonstrates that vitamin K neutralises vitamin-D-induced hypercalcaemia. Excessive vitamin D signalling can increase calcium exposure through mechanisms that remain dangerous regardless of whether vitamin-K-dependent proteins are adequately carboxylated.

That boundary is especially important when translating mechanistic nutrient interactions into consumer advice.

What the combined evidence establishes

The evidence supports a complementary relationship in which vitamin D contributes to calcium availability, endocrine regulation and expression of some target proteins, while vitamin K supports activation of specific calcium-binding proteins through carboxylation.

It supports meaningful changes in osteocalcin and MGP biomarkers with vitamin K intervention and supports bone benefit from combined therapy in some osteoporosis populations.

It does not establish a universal skeletal benefit, does not show that vitamin K status reveals a hidden vitamin D bone benefit in generally healthy adults, and does not show that MK-7 plus vitamin D prevents progression of established aortic-valve calcification.

The most defensible physiology-first conclusion is therefore that vitamin D and vitamin K perform complementary but non-identical functions within calcium and mineral regulation. Their interaction is biologically real, while the downstream clinical consequences remain dependent on population, tissue, baseline state and the endpoint being measured.

Scientific sources

Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. PMID: 9076586.

The combination effect of vitamin K and vitamin D on human bone quality: a meta-analysis of randomized controlled trials. PMID: 32219282.

Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL. PMID: 42524357.

Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. PMID: 35465686.

The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial. PMID: 34845313.

Related reading

Original sources

Source

The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial

The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis.

Publication details

The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial. PMID: 34845313.

Read more →